Short answer
RASopathy genetic testing usually means a targeted multigene panel, sometimes followed by exome or genome testing, to look for inherited changes in the RAS/MAPK pathway. It is most useful when the physical findings, heart findings, skin findings, or prenatal ultrasound clues point toward a specific syndrome such as Noonan syndrome, cardiofaciocutaneous syndrome, Costello syndrome, or a related overlapping condition.
Which syndromes are on the table
| Syndrome or overlap | Typical genes | Why the panel matters |
|---|---|---|
| Noonan syndrome spectrum | PTPN11, SOS1, RAF1, RIT1, LZTR1, KRAS, NRAS, MRAS, and related genes | Often linked to congenital heart disease, short stature, and facial or lymphatic clues. |
| Cardiofaciocutaneous syndrome | BRAF, MAP2K1, MAP2K2, KRAS | More likely when skin, hair, feeding, and neurodevelopmental findings are prominent. |
| Costello syndrome | HRAS | Important because cancer risk, arrhythmia, and feeding issues can shape follow-up. |
| Legius / NF1 overlap | SPRED1, NF1 | Considered when café-au-lait spots, macrocephaly, or learning issues raise the question of a broader RASopathy overlap. |
When the test may fit
Testing often starts with a clear clinical question: is this Noonan spectrum, CFC, Costello, or a different overlap condition? The more specific the phenotype, the more useful a panel can be. Congenital heart disease, short stature, feeding problems, characteristic facial features, skin and hair changes, or a family history of a known variant are common reasons to order testing.
In prenatal care, increased nuchal translucency, cystic hygroma, hydrops, or unexplained heart or lymphatic findings can be reasons to discuss RASopathy testing after the chromosome-level questions have been addressed.
Prenatal clues and family history
Many RASopathies are de novo, but family history still matters because autosomal dominant inheritance is common in this group. If a parent already has a known variant, targeted familial testing is usually more efficient than a broad panel. If the family history is unclear, a genetics team may use the phenotype, ultrasound, and prior chromosome testing to decide whether a panel or exome-style approach makes more sense.
That distinction matters because the result can affect pregnancy counseling, newborn planning, and how soon cardiology or developmental follow-up begins after birth.
Why a negative result does not always settle the question
A negative panel does not always rule out a RASopathy. The family may have a variant that was not captured, a mosaic result, a gene not yet included on the panel, or a phenotype that needs time to become obvious. In that setting, the result should be interpreted together with the physical exam, cardiac testing, and family history rather than in isolation.
That is why the question is not simply whether the panel is positive. It is whether the result changes surveillance, counseling, or who in the family needs testing next.
Questions to ask
- Which syndrome is most likely from the current phenotype: Noonan, CFC, Costello, Legius, or another overlap?
- Does the test include the key RAS/MAPK genes, plus deletion or duplication analysis if needed?
- Would a broader exome or genome approach be better if the findings are mixed?
- Should the result change cardiac, developmental, skin, feeding, or cancer-risk follow-up?
- Could a VUS create uncertainty without changing management right away?
FAQ
What does RASopathy genetic testing look for?
It looks for inherited changes in RAS/MAPK pathway genes that can explain a Noonan-spectrum, CFC, Costello, or related phenotype.
Which genes are usually involved?
Common genes include PTPN11, SOS1, RAF1, RIT1, LZTR1, KRAS, NRAS, BRAF, MAP2K1, MAP2K2, HRAS, and sometimes SPRED1 or NF1 depending on the overlap question.
Does a negative panel rule out a RASopathy?
No. It can lower the chance, but it does not rule it out because not every cause is detectable on every panel.
When does prenatal testing matter most?
It matters most when ultrasound findings, a known family variant, or a strong Noonan-spectrum clue changes pregnancy counseling or newborn planning.
Why is family history so important?
Many RASopathies are autosomal dominant, so a known family variant can make targeted testing more useful than a broad panel.
What if the result is a VUS?
A VUS should be interpreted cautiously and usually should not be used by itself to make major medical decisions.
Related guides: genetic counselor guide, prenatal screening versus diagnostic testing, hereditary cardiomyopathy genetic testing, and whole genome sequencing reports.